Effectiveness of a nurse-led telephone follow-up in the therapeutic management of patients receiving oral antineoplastic agents: a randomized, multicenter controlled trial (ETICCO study)
- 7 January 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Supportive Care in Cancer
- Vol. 29 (8), 4257-4267
- https://doi.org/10.1007/s00520-020-05955-3
Abstract
Purpose The use of oral cancer drugs (OAD) has increased over the last two decades. The objective of this study was to measure the impact of a nurse-led telephone follow-up in the therapeutic management of patients treated with an OAD regarding toxicity, medication adherence and quality of life. Methods A randomized, multicenter, controlled trial was conducted. All consecutive over 18-year-old patients, treated in medical oncology, radiotherapy, or hematology departments, receiving OAD for any cancer were invited to participate to the study. A total of 183 patients treated for solid or hematological cancers with an OAD were randomly assigned to receive a nurse-led telephone follow-up or standard care for 24 weeks. Data were collected between 2015 and 2018. Results Nurse telephone follow-up did not improve the global score toxicity in the intervention group. However, telephone calls directed by trained nurses induced a significant decrease in number of patients with grade 3 adverse events throughout the follow-up [OR 0.45 (IC à 95%) (0.23, 0.9)](P = 0.03). There was no significant difference in quality of life and medication adherence between groups at any follow-up time point. Conclusions In this first French real-life study, the advice provided by qualified nurses via phone calls improved the management of grade 3 toxicities but failed to demonstrate an improvement of all grades of toxicities. More prospective studies are needed to confirm the impact of telephone calls on the toxicities related to OAD. Trial registration Clinical trial registration is NCT02459483. Protection committee SUD-ESTI registration is 2015-A00527-42 on 13 April 2015. National Agency for the Safety of Medicines and Health Products registration is 150619-B on the 27 may 2015.Funding Information
- « Le réseau espace santé cancer Rhones-Alpes: INNOV’RA 2014 », (NA)
- La ligue contre le cancer (NA)
- Novartis Pharma SAS (NA)
This publication has 29 references indexed in Scilit:
- Assessing adherence to oral chemotherapy using different measurement methods: Lessons learned from capecitabineJournal of Oncology Pharmacy Practice, 2013
- Is a nurse-led telephone intervention a viable alternative to nurse-led home care and standard care for patients receiving oral capecitabine? Results from a large prospective audit in patients with colorectal cancerEuropean Journal of Cancer Care, 2013
- Interventions to Promote Adherence With Oral AgentsSeminars in Oncology Nursing, 2011
- Oral Cancer Chemotherapy: The Critical Interplay Between Patient Education and Patient SafetyCurrent Oncology Reports, 2010
- Effectiveness of a Home Care Nursing Program in the Symptom Management of Patients With Colorectal and Breast Cancer Receiving Oral Chemotherapy: A Randomized, Controlled TrialJournal of Clinical Oncology, 2009
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2008
- Effective oral chemotherapy for breast cancer: pillars of strengthAnnals of Oncology, 2008
- Capecitabine: A reviewClinical Therapeutics, 2005
- Implementation of capecitabine (Xeloda®) into a cancer centre: UK experienceEuropean Journal of Oncology Nursing, 2004